Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Curetis to benefit from bioMérieux's BioFire swoop?

This article was originally published in Clinica

Executive Summary

Infectious disease molecular diagnostics specialist Curetis has seen increasing interest in its technology from some of the larger players since the acquisition of rival BioFire Diagnostics by France’s bioMérieux. The Marcy l’Etoile shelled out $450m, plus debt, for BioFire and its FilmArray platform earlier this month, in a deal that was too rich for some analysts (www.clinica.co.uk, 5 September 2013).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT100855

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel